R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Eloise McLennan interview with Peter Stenico

Reuters Pharma Europe 2024 – Peter Stenico

Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.

R&D

London’s life sciences scene upbeat as 2024 conference seaso...

With 2024 well under way, influential conferences in London have given a barometer reading on the conditions in the European biopharma market, reports Richard Staines.

R&D

Proving ROI for digital endpoints

The costs associated with clinical trials are a major bottleneck to drug development and affordability.

R&D

The end of drug shortages begins with data transparency

For more than 15 years, shortages of critical drugs — from oncology treatments to emergency room and surgical suite essentials — have burdened healthcare systems and compromised patient car

R&D

Pharma gets ruthless as job losses mount across industry

The industry is showing its teeth, as companies have started slashing positions.

R&D

Life sciences in Ireland: Nurturing talent, innovating excel...

Late last month, pharmaphorum was invited on an IDA Ireland-organised press tour of the life sciences industry in Ireland’s West, permitting an inside peek into the world-class life science